Militia Capital Management LLC Makes New $565,000 Investment in BioAge Labs, Inc. $BIOA

Militia Capital Management LLC bought a new position in BioAge Labs, Inc. (NASDAQ:BIOA) in the first quarter, HoldingsChannel.com reports. The institutional investor bought 32,286 shares of the company’s stock, valued at approximately $565,000.

Other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC grew its position in shares of BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of BioAge Labs in the 3rd quarter valued at $27,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of BioAge Labs during the 4th quarter valued at $77,000. Nisa Investment Advisors LLC lifted its position in shares of BioAge Labs by 4,219.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after acquiring an additional 10,000 shares during the period. Finally, Bank of America Corp DE boosted its stake in BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after acquiring an additional 3,517 shares in the last quarter.

BioAge Labs Stock Down 0.2%

Shares of BIOA opened at $21.90 on Friday. BioAge Labs, Inc. has a 12-month low of $4.11 and a 12-month high of $25.95. The business’s fifty day moving average is $20.17 and its 200 day moving average is $19.30. The stock has a market cap of $973.52 million, a P/E ratio of -9.12 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The business had revenue of $2.77 million during the quarter. On average, analysts expect that BioAge Labs, Inc. will post -2.68 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on BIOA shares. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Needham & Company LLC began coverage on shares of BioAge Labs in a report on Friday, March 27th. They set a “buy” rating and a $50.00 price objective on the stock. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. BTIG Research assumed coverage on BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 target price for the company. Finally, Roth Capital started coverage on BioAge Labs in a research report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BioAge Labs presently has an average rating of “Moderate Buy” and an average price target of $43.50.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.